相关临床试验
2
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
尚未招募
2
100.0%
暂无批准数据
- Biolexis Therapeutics has successfully resolved the cryoEM structure of BLX-7006, confirming a first-in-class allosteric activation mechanism for the GLP-1 receptor that differs from all existing approaches. - The breakthrough validates the company's AI-enabled MolecuLern platform, which identified BLX-7006 as a completely new chemotype with superior metabolic stability compared to modified analogs like Danuglipron and Orforglipron. - Toxicology and manufacturing studies are underway to support clinical testing, with first-in-human trials planned for Q3 2025 targeting obesity, type 2 diabetes, and metabolic dysfunction.
• The NLRP3 protein inhibitors pipeline is robust, with over 20 companies developing more than 25 inhibitors targeting various inflammatory conditions. • NLRP3 inhibitors are being explored for treating neurodegenerative diseases like Alzheimer’s and Parkinson’s, as well as metabolic conditions such as NASH. • Clinical trials are underway, with companies like Novo Nordisk and NodThera reporting positive data on their NLRP3 inhibitor candidates. • Collaborations, such as the one between Halia Therapeutics and Biolexis Therapeutics, are advancing the development of brain-penetrant NLRP3 inhibitors for neuroinflammation.
